Literature DB >> 10990059

Choroideremia associated with subretinal neovascular membrane.

K Endo1, M Yuzawa, N Ohba.   

Abstract

PURPOSE: To report two Japanese patients with choroideremia, one male and one heterozygous female, who developed subretinal neovascular membrane and/or subretinal fibrosis in the intermediate stage of the disease, and, in addition, to describe marked clinical manifestation in a heterozygous carrier female.
METHOD: Two patients were examined by slip-lamp biomicroscopy, ophthalmoscopy and other ophthalmoloscopic examinations.
RESULTS: Two cases showed moderately advanced ophthalmoscopic and functional abnormalitities compatible with choroideremia, and in addition, subretinal lesion in the fovea and/or midperiphery.
CONCLUSION: The intermediate stage of choroideremia may occasionally be complicated with choroidal neovascular membrane in the fovea, the midperiphery, or both, which resolves spontaneously and results in subretinal fibrous scarring. The occurrence of this complication in the fovea leads to episodic central visual loss, while midperipheral lesion may remain unrecognized.

Entities:  

Mesh:

Year:  2000        PMID: 10990059     DOI: 10.1034/j.1600-0420.2000.078004483.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  11 in total

1.  Spectrum of Disease Severity and Phenotype in Choroideremia Carriers.

Authors:  Ruben Jauregui; Karen Sophia Park; Akemi J Tanaka; Ahra Cho; Maarjaliis Paavo; Jana Zernant; Jasmine H Francis; Rando Allikmets; Janet R Sparrow; Stephen H Tsang
Journal:  Am J Ophthalmol       Date:  2019-06-08       Impact factor: 5.258

2.  Choroidal neovascularization in 36 eyes of children and adolescents.

Authors:  P Rishi; A Gupta; E Rishi; B J Shah
Journal:  Eye (Lond)       Date:  2013-07-26       Impact factor: 3.775

3.  Choroideremia: analysis of the retina from a female symptomatic carrier.

Authors:  Vera L Bonilha; Karmen M Trzupek; Yong Li; Peter J Francis; Joe G Hollyfield; Mary E Rayborn; Nizar Smaoui; Richard G Weleber
Journal:  Ophthalmic Genet       Date:  2008-09       Impact factor: 1.803

4.  A novel mutation (967-970+2)delAAAGGT in the choroideremia gene found in a Japanese family and related clinical findings.

Authors:  Yutaka Iino; Takuro Fujimaki; Keiko Fujiki; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

5.  Silencing of the CHM gene alters phagocytic and secretory pathways in the retinal pigment epithelium.

Authors:  Nataliya V Gordiyenko; Robert N Fariss; Connie Zhi; Ian M MacDonald
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-09       Impact factor: 4.799

6.  Choroidal neovascularization in 111 eyes of children and adolescents.

Authors:  Pukhraj Rishi; Rekha Priya Kalluri Bharat; Ekta Rishi; Muna Bhende; Jyotirmay Biswas; Arshee Ahmed; Sridharan Sudharshan
Journal:  Int Ophthalmol       Date:  2021-08-23       Impact factor: 2.031

7.  Novel CHM mutations in Polish patients with choroideremia - an orphan disease with close perspective of treatment.

Authors:  Anna Skorczyk-Werner; Anna Wawrocka; Natalia Kochalska; Maciej Robert Krawczynski
Journal:  Orphanet J Rare Dis       Date:  2018-12-12       Impact factor: 4.123

8.  Pathogenic mechanisms and the prospect of gene therapy for choroideremia.

Authors:  Ioannis S Dimopoulos; Stephanie Chan; Robert E MacLaren; Ian M MacDonald
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-01       Impact factor: 0.694

9.  Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab.

Authors:  Neal V Palejwala; Andreas K Lauer; Richard G Weleber
Journal:  Clin Ophthalmol       Date:  2014-09-01

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.